Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
about
Eradication of bone marrow minimal residual disease may prompt early treatment discontinuation in CLL.New approaches to manipulate minimal residual disease after allogeneic stem cell transplantation.A single tube 10-color flow cytometry assay optimizes detection of minimal residual disease in chronic lymphocytic leukemia.
P2860
Post-remission intervention with alemtuzumab or rituximab to eradicate minimal residual disease in chronic lymphocytic leukemia: where do we stand?
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Post-remission intervention wi ...... c leukemia: where do we stand?
@en
Post-remission intervention wi ...... c leukemia: where do we stand?
@nl
type
label
Post-remission intervention wi ...... c leukemia: where do we stand?
@en
Post-remission intervention wi ...... c leukemia: where do we stand?
@nl
prefLabel
Post-remission intervention wi ...... c leukemia: where do we stand?
@en
Post-remission intervention wi ...... c leukemia: where do we stand?
@nl
P2093
P2860
P1433
P1476
Post-remission intervention wi ...... c leukemia: where do we stand?
@en
P2093
Caroline Dartigeas
Eric Van Den Neste
Loïc Ysebaert
Pierre Feugier
Rémi Letestu
Stéphane Leprêtre
Thérèse Aurran-Schleinitz
P2860
P304
P356
10.3109/10428194.2011.608450
P577
2011-09-19T00:00:00Z